Feed / CGON

CG Oncology, Inc.

CGON

Healthcare · 78.97 +0.9% today

Isolated · not yet confirmedMarket checked 25 Aug, 15:55 GMT-4

Jodie situation report

CG Oncology, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.

Company+0.9% todayVolume comparison unavailable
Market group0 of 37 activeBiotechnology · unavailable
Disclosed network0 of 4 confirmingNo filing-linked name is confirming now
What would change this read
  • External clinical-trial expenses rose materially in the latest three months, primarily because of higher CMC costs and increased headcount.
  • Reported $14.5M increase in external clinical trial expenses tied to higher CMC costs for the quarter ended March 31, 2026.

Invalidation: The isolated read changes if CGON's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind CGON

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

JEFJefferies Financial Group Inc.investeeMay 8, 2026

On March 28, 2025, we entered into an Open Market Sale Agreement SM (Jefferies Sales Agreement) with Jefferies LLC, as agent, pursuant to which we may offer and sell, from time to time through Jefferies, shares of our common stock.

MRKMerck & Company, Inc.partnerFeb 27, 2026

We entered into a clinical trial collaboration and supply agreement with Merck providing at no-cost supply of pembrolizumab for use in CORE-001 (which agreement also provides for the joint ownership of clinical trial data but has no additional financial oblig…

Depended on by

URGNUroGen Pharma Ltd.competitorMar 2, 2026

We are aware of several pharmaceutical companies that are developing drugs in the general fields of urology and uro-oncology, such as AstraZeneca, Aura Biosciences., Bristol Myers Squibb, CG Oncology, enGene Holdings, Ferring Pharmaceuticals, Fidia Pharmaceut…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CGON is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.